Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

2016 NCCN Fellows Recognition Program Explores New Horizons in Quality Cancer Care

On Sunday, April 3, 2016, the National Comprehensive Cancer Network® (NCCN®) hosted more than 60 fellows during 2016 NCCN Fellows Recognition Program: New Horizons in Quality Cancer Care™, which was held in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™ at The Diplomat in Hollywood, Florida. This half-day program is dedicated to providing fellows from leading U.S. cancer centers with the opportunity to hear from world-class specialists about the latest treatment advances in particular disease sites.

The program commenced with a discussion around advances in the management of relapsed/refractory multiple myeloma and Waldenström’s Marcoglobulinemia. Steven P. Treon, MD, PhD, Dana-Farber/Brigham and Women’s Cancer Center compared current treatments, as well as summarized emerging data with novel agents and combination regimens for the diseases.

Following Dr. Treon, Robert J. Morgan, MD, City of Hope Comprehensive Cancer Center, explored recurrence therapy for ovarian cancer, outlining specific categories of recurrence therapies for ovarian cancer and assessed recent recommendations for such therapies in patients, including appropriate dose selection, sequencing, adverse event management, and when to cease therapy.

During their presentation on surgical approaches to systemic therapies in the management of kidney cancer, Steven L. Chang, MD, MS, and Toni K. Choueiri, MD, Dana-Farber/Brigham and Women’s Cancer Center, summarized the benefits and risks of current surgical and systemic treatment options and evaluated the promising immunotherapy approaches currently being studied in clinical trials.

Billy W. Loo, Jr., MD, PhD, Stanford Cancer Institute, followed with a presentation on recent advances in radiation therapy for non-small cell lung cancer, including stereotactic ablative radiotherapy (SABR) in early-stage lung cancer and highly conformal radiation therapy in locally advanced lung cancer.

During the day’s final presentation, Al B. Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Doulas W. Blayney, MD, Stanford Cancer Institute, discussed the variances between careers at academic centers versus community hospitals. Dr. Benson and Dr. Blayney touched on important considerations for the fellows in attendance, including but not limited to determination of personal priorities, definitions of career success, desire to teach, and salary.

NCCN plans to hold the next NCCN Fellows Recognition Program during the NCCN 22nd Annual Conference in 2017 in Orlando, Florida.